opioid sparing analgesia post-thoracotomy
Phase 3
Recruiting
- Conditions
- SurgeryAnaesthesia
- Registration Number
- PACTR202104609519383
- Lead Sponsor
- Dr mona raafat elghamry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
patients of both sex,
American Society of Anesthesiologists (ASA) physical status I, II and III,
aged 20 to 80 years
selected for open thoracic surgery
Exclusion Criteria
Patients with allergy to nalbuphine or morphine;
opioid abuse,
history of chronic pain,
recurrent operation,
pregnancy;
uncontrolled hepatic or renal diseases;
neurologic or psychiatric illnesses that would interfere with assessment of pain score
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie nalbuphine's opioid-sparing effect after thoracotomy?
How does preemptive subcutaneous nalbuphine compare to standard opioid analgesia in post-thoracotomy pain management?
Are there specific biomarkers that predict analgesic response to nalbuphine in thoracic surgery patients?
What adverse events are associated with preemptive nalbuphine administration in thoracic surgery?
What combination analgesic strategies with nalbuphine show promise for post-thoracotomy pain reduction?